Neurocrine Biosciences, Inc.

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			After hours 01:49:43 am
159.76 ^USD	-1.81%		166.24	+4.06%

09/06	Neurocrine Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09:20 AM
09/06	Neurocrine Biosciences Late-Stage Study Shows Promising Results for Tardive Dyskinesia Drug	MT

Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says

Published on 05/06/2026 at 09:13 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Neurocrine Biosciences, Inc.

09/06	Neurocrine Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09:20 AM
09/06	Neurocrine Biosciences Late-Stage Study Shows Promising Results for Tardive Dyskinesia Drug	MT
09/06	Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia Reinforcing the Efficacy of INGREZZA Capsules Across A Broad Range of Patients	CI
08/06	Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-Emotional Improvements with Ingrezza Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities	CI
05/06	Neurocrine Biosciences Insider Sold Shares Worth $5,770,235, According to a Recent SEC Filing	MT
02/06	Neurocrine Biosciences, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10:40 AM
29/05	Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says	MT
29/05	RBC Lifts Price Target on Neurocrine Biosciences to $183 From $180, Keeps Outperform Rating	MT
22/05	Bernstein Initiates Coverage on Neurocrine Biosciences With Outperform Rating	MT
19/05	Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules	MT
19/05	Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with Ingrezza (Valbenazine) Capsules	CI
18/05	Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others.	CI
18/05	Neurocrine Biosciences completes acquisition of Soleno Therapeutics	RE
18/05	Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics	MT
18/05	Neurocrine Biosciences, Inc. Enters into A Credit Agreement	CI

Chart Neurocrine Biosciences, Inc.

Duration

Period

NBIX: Dynamic Chart

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâ€™s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampatorà¥¥ / (AMPA PAM) and others.

Employees

2,000

Sector

Pharmaceuticals

More about the company